Company: BLUWU
Filing Date: 2025-03-31
Form Type: S-1/A
Source: 0001641172-25-001410
Chunk: 159

Company: Blue Water Acquisition Corp. III
Filing Date: 2025-03-31
Form: S-1/A
Chunk 159
---
 2001, and Digene Corp., a medical diagnostics firm (acquired by Qiagen NV (NYSE: QGEN)) from 2005 to 2009, Mr. Hernandez founded and became the President and Chief Executive Officer of Innovative Biosensors, Inc., a biotech company, from 2004 to 2009. Later, Mr. Hernandez served as the Founder and Chairman of Microlin Bio Inc., a biopharmaceutical company, from August 2013 to January 2017, and as Chairman of the Board of Ember Therapeutics, Inc. (OTCMKTS: EMBT) from April 2014 to January 2019. He was also the Chairman of Sydys Corporation from May 2016 to January 2019. In 2018, Mr. Hernandez founded Blue Water Vaccines Inc., an early stage biotechnology company focused on manufacturing a universal influenza vaccine in partnership with the University of Oxford in England. In January 2020 he founded, and in May 2020 sold, Noachis Terra, Inc. (acquired by Qiagen NV (NYSE: OGEN)) a company developing a vaccine for COVID-19. From May 2020 to September 2021, Mr. Hernandez was the Chairman and Chief Executive Officer of Blue Water Acquisition Corp. (Nasdaq: BLUW) (“Blue Water I”), a special purpose acquisition company which completed its initial public offering in December 2020. On September 9, 2021, Blue Water I consummated a business combination with Clarus Therapeutics Inc., a pharmaceutical company. Mr. Hernandez served as a director of the post-combination entity, Clarus Therapeutics Holdings Inc. (Nasdaq: CRXT), until August 2022. Mr. Hernandez brings experience in managing and interacting with diverse cultures, high level executives, and elected officials, to the team. Mr. Hernandez received a B.S. in Neuroscience, an M.Sc. in Molecular Genetics and Microbiology and an M.B.A. from the University of Florida. He also holds an M.Sc. in Chronic Disease Epidemiology and Biostatics from Yale University and is currently pursuing a M.Sc. in Global Healthcare Leadership at University of Oxford in the United Kingdom.

| 107 |

Martha F. Ross,our Chief Financial Officer, brings over 25 years of global financial, strategic growth and accounting leadership experience in tech, manufacturing, communications and electric power generation, including expertise in various government funded and